Business Wire - August 26, 2003

Both countries are experiencing rapidly increasing incidences of sexually transmitted diseases (STDs). With a total 2.3 billion people, India and China have about 40% of world's population. Based on U.S. genital infection rates of 1 in 4 adults, an estimated 575,000,000 people in China and India could be infected.

"We will work closely with the two governments and select national companies to make these products available for distribution in India and China within the next twelve to eighteen months. There is a growing STD problem in these countries and strong evidence of an HIV, HSV connection. Recent studies conducted in Pune, India, have shown that those HSV infected people have a five times greater chance of contracting HIV as compared to non-HSV positive people with similar risks. This suggests that controlling the spread of genital herpes will help reduce the number HIV cases," states Mr. David Lane, Phanuel's managing director and CEO.

Dr. Malcolm Skolnick, CytoGenix' CEO, comments, "These transactions further validate our business model and we have every expectation that Phanuel's business experience and relationships in China and India will insure the success of this project over the next few years."

CytoGenix Inc. is a biopharmaceutical company that develops and markets innovative products and services based on its proprietary DNA expression technology. CytoGenix has products in pre-clinical development including, anti-herpes, anti-psoriasis and anti-inflammatory topical creams. The company owns a U.S. patent for its core DNA expression technology and has 40 international or U.S. pending patent applications.

SAFE HARBOR: Except for statements of historical fact, the statements in this press release are forward-looking. Such statements are subject to a number of risks and uncertainties that could cause actual results to differ materially from the statements made. These factors include, but are not limited to, general economic conditions, risks associated with the acceptance of new products, competition, and other factors more fully detailed in the company's filings with the Securities and Exchange Commission. Additional information about CytoGenix and its technology can be found on the Web site at www.cytogenix.com.

CONTACT: CytoGenix Inc., Houston

Juan Ferreira, 407-774-9949

SOURCE: CytoGenix Inc.

030826
BW030806

Copyright © 2003 - Business Wire. All rights reserved. Reproduced with permission. Reproduction of this article (other than one copy for personal reference) must be cleared through the Business Wire, Permissions Desk, Business Wire, 1185 Avenue of the Americas, 3rd Floor, New York, NY 10036; Tel: (212) 575-8822; FAX: (212) 575-1854. http://www.businesswire.com.

AEGiS is made possible through unrestricted grants from Boehringer Ingelheim, Elton John AIDS Foundation, iMetrikus, Inc., John M. Lloyd Foundation, the National Library of Medicine, and donations from users like you. Always watch for outdated information. This article first appeared in 2003. This material is designed to support, not replace, the relationship that exists between you and your doctor.

AEGiS presents published material, reprinted with permission and neither endorses nor opposes any material. All information contained on this website, including information relating to health conditions, products, and treatments, is for informational purposes only. It is often presented in summary or aggregate form. It is not meant to be a substitute for the advice provided by your own physician or other medical professionals. Always discuss treatment options with a doctor who specializes in treating HIV.

Copyright ©1980, 2003. AEGiS. All materials appearing on AEGiS are protected by copyright as a collective work or compilation under U.S. copyright and other laws and are the property of AEGiS, or the party credited as the provider of the content. .